Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Definition of a Prognostic Risk-Classifier Based on SNPs Array Analysis of Copy Number Alterations in Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients

Blood (2017) 130 (Supplement 1): 3053.

https://doi.org/10.1182/blood.V130.Suppl_1.3053.3053

Published: 2017

Journal Articles

Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors

Paola Minetto, MD, Debora Soncini, PhD, Antonia Cagnetta, MD, Fabio Guolo, MD, Veronica Retali, Giulia Rivoli, MD, Nadia Bisso, MD, Nikki Di Felice, MD, Maurizio Miglino, PhD, Letizia Canepa, MD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD, Michele Cea

Blood (2017) 130 (Supplement 1): 1796.

https://doi.org/10.1182/blood.V130.Suppl_1.1796.1796

Published: 2017

Journal Articles

CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents

Michele Cea, MD, Antonia Cagnetta, MD, Debora Soncini, PhD, Paola Minetto, MD, Micaela Bergamaschi, MD, Giulia Rivoli, MD, Letizia Canepa, MD, Marco Gobbi, MD, Roberto M Lemoli, MD

Blood (2016) 128 (22): 5671.

https://doi.org/10.1182/blood.V128.22.5671.5671

Published: 2016

Journal Articles

Prognostic Implication of Somatic Mutations By Next Generation Sequencing: An Analysis from the Mmrf Commpass Study in Newly Diagnosed Multiple Myeloma Patients

Blood (2016) 128 (22): 2079.

https://doi.org/10.1182/blood.V128.22.2079.2079

Published: 2016

Journal Articles

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Davide Lovera, MD, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Micaela Bergamaschi, MD, Sara Aquino, MD, Fabio Guolo, MD, Paola Minetto, MD, Filippo Ballerini, MD, Letizia Canepa, MD, Sophia Adamia, PhD, Alessio Nencioni, Ivana Pierri, MD, Marino Clavio, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2015) 126 (23): 1375.

https://doi.org/10.1182/blood.V126.23.1375.1375

Published: 2015

Journal Articles

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Annamaria Brioli, MD, Annalisa Pezzi, Statistician, Daniele Derudas, MD, Maria Concetta Petti, MD, Beatrice Anna Zannetti, MD, Felicetto Ferrara, MD, Serena Rocchi, MD, Francesco Nobile, MD, Anna Baraldi, MD, Pellegrino Musto, MD, Francesco Lanza, MD, Katia Mancuso, MD, Letizia Canepa, MD, Lucio Catalano, MD, Antonio Lazzaro, MD, Graziella Pinotti, MD, Mario Boccadoro, MD, Michele Cavo, MD

Blood (2014) 124 (21): 1182.

https://doi.org/10.1182/blood.V124.21.1182.1182

Published: 2014

Journal Articles

How We Treat Chronic Myeloid Leukemia Patients During Daily Practice? Case Studies From The Real Life Experience Of Two Genoa Centers Of Hematology

Laura Mitscheunig, Micaela Bergamaschi, MD, Raffalla Grosso, Maurizio Miglino, PHD, Marino Clavio, MD, Filippo Ballerini, PHD, Letizia Canepa, MD, Riccardo Varaldo, Roberto Lemoli, Marco Gobbi, MD, Ivana Pierri, MD

Blood (2013) 122 (21): 5192.

https://doi.org/10.1182/blood.V122.21.5192.5192

Published: 2013

Journal Articles

Combined overexpression of WT1 and BAALC genes May Predict AML evolution in MDS Patients

Daniele Avenoso, MD, Enrico De Astis, MD, Nicoletta Colombo, Raffaella Grasso, PhD, Micaela Bergamaschi, MD, Paola Minetto, MD, Sara Aquino, PHD, Davide Lovera, MD, Fabio Cruciani, MD, Fabio Guolo, MD, Filippo Ballerini, PHD, Marino Clavio, MD, Letizia Canepa, MD, Ivana Pierri, MD, Carlo Marani, MD, Marco Gobbi, MD, Maurizio Miglino, PHD

Blood (2013) 122 (21): 5204.

https://doi.org/10.1182/blood.V122.21.5204.5204

Published: 2013

Journal Articles

Efficacy and Tolerability Of Frontline Oral Fludarabine and Cyclophosphamide Combination Therapy For Elderly Patients With Chronic B-Cell Lymphocytic Leukaemia and Low Grade Non Hodgkin Lymphoma

Micaela Bergamaschi, MD, Laura Mitscheunig, Fabio Guolo, MD, Anna Ghiso, Federica Galaverna, Maurizio Miglino, PHD, Marino Clavio, MD, Filippo Ballerini, PHD, Letizia Canepa, MD, Roberto Lemoli, Marco Gobbi, MD, Ivana Pierri, MD

Blood (2013) 122 (21): 5095.

https://doi.org/10.1182/blood.V122.21.5095.5095

Published: 2013

Journal Articles

High WT1 Expression Has An Independent Positive Influence On CR Rate and EFS in Non M3 AML Patients Treated with Chemotherapy.

Nicoletta Colombo, Raffaella Grasso, Maurizio Miglino, Marino Clavio, Gianmatteo Pica, MD, Germana Beltrami, Micaela Bergamaschi, Carlo Marani, Antonia Cagnetta, Anna Ghiso, Laura Mitscheunig, Ivana Pierri, Filippo Ballerini, Letizia Canepa, Sara Aquino, Enrico De Astis, Angelo Michele Carella, Marco Gobbi

Blood (2009) 114 (22): 4675.

https://doi.org/10.1182/blood.V114.22.4675.4675

Published: 2009

Journal Articles

A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients.

Federica Cavallo, MD, Alessandra Larocca, MD, Maria Teresa Petrucci, MD, Vincenzo Federico, MD, Antonietta Pia Falcone, MD, Grazia Sanpaolo, MD, Letizia Canepa, MD, Monica Crugnola, MD, Mario Boccadoro, MD, Antonio Palumbo, MD

Blood (2009) 114 (22): 2864.

https://doi.org/10.1182/blood.V114.22.2864.2864

Published: 2009

Journal Articles

Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results

Antonio Palumbo, MD, Patrizia Falco, MD, Francesca Gay, MD, Paolo Corradini, MD, Claudia Crippa, MD, Francesco Di Raimondo, MD, Antonietta Falcone, MD, Nicola Giuliani, MD, Pellegrino Musto, MD, Fortunato Morabito, MD, Letizia Canepa, MD, Alessandro Gozzetti, MD, Simona Caltagirone, PhD, Jerome B. Zeldis, MD, Robert D. Knight, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2008) 112 (11): 2768.

https://doi.org/10.1182/blood.V112.11.2768.2768

Published: 2008

Journal Articles

Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial

Antonio Palumbo, MD, Patrizia Falco, MD, Grazia Sanpaolo, MD, Antonietta Falcone, MD, Vincenzo Ferderico, MD, Letizia Canepa, MD, Monica Crugnola, MD, Luca Baldini, MD, Alessandra Larocca, MD, Valeria Magarotto, MD, Maria Teresa Petrucci, MD, Mario Boccadoro, MD

Blood (2008) 112 (11): 868.

https://doi.org/10.1182/blood.V112.11.868.868

Published: 2008

Journal Articles

Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.

Antonio Palumbo, MD, Patrizia Falco, MD, Antonietta Falcone, MD, Paolo Corradini, MD, Francesco Di Raimondo, MD, Nicola Giuliani, MD, Giuseppe Rossi, MD, Fortunato Morabito, MD, Letizia Canepa, MD, Alessandro Gozzetti, MD, Maria Teresa Ambrosini, MD, Jerome Zeldis, MD, Robert Knight, MD, Robin Foà, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2006) 108 (11): 800.

https://doi.org/10.1182/blood.V108.11.800.800

Published: 2006

NARROW

Definition of a Prognostic Risk-Classifier Based on SNPs Array Analysis of Copy Number Alterations in Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients

Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors

CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents

Prognostic Implication of Somatic Mutations By Next Generation Sequencing: An Analysis from the Mmrf Commpass Study in Newly Diagnosed Multiple Myeloma Patients

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

How We Treat Chronic Myeloid Leukemia Patients During Daily Practice? Case Studies From The Real Life Experience Of Two Genoa Centers Of Hematology

Combined overexpression of WT1 and BAALC genes May Predict AML evolution in MDS Patients

Efficacy and Tolerability Of Frontline Oral Fludarabine and Cyclophosphamide Combination Therapy For Elderly Patients With Chronic B-Cell Lymphocytic Leukaemia and Low Grade Non Hodgkin Lymphoma

High WT1 Expression Has An Independent Positive Influence On CR Rate and EFS in Non M3 AML Patients Treated with Chemotherapy.

A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients.

Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results

Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial

Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only